stem cell therapy

FDA approves JointStem, an arthritis-specialized stem cell therapy

By The AsiaN Editor SEOUL: JointStem, the world’s first self-fat-derived mid-leaf cell treatment for severe degenerative arthritis, has passed the U.S. Food and Drug Administration’s commercial clinical 2b/3a review, Nature Cell Co has announced. This provides a meaningful opportunity to open the era of treating U.S. patients with Korean stem…

Read More »